The in vivo efficacy of docetaxel and cabazitaxel in a cell-line based xenograft of castration-resistant prostate cancer (CRPC) previously treated with enzalutamide.
Robert J. van Soest
No relevant relationships to disclose
Ellen S. de Morrée
No relevant relationships to disclose
Corrina M.A. de Ridder
No relevant relationships to disclose
Herman Burger
No relevant relationships to disclose
Erik A.C. Wiemer
No relevant relationships to disclose
Ron H.J. Mathijssen
No relevant relationships to disclose
Wytske M. van Weerden
No relevant relationships to disclose
Ronald De Wit
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi